The Detection & Expression of Circulating miRNAs as Biomarkers Hold High Clinical Implications for Predicting Prostate Cancer Recurrence Post Radical Prostatectomy.

Currently, there is limited technology available for accurately predicting high-risk cancer biochemical recurrence (BCR). As such, there is a significant clinical need to discover non-invasive biomarkers in hopes to identify these high-risk patients and prevent unnecessary therapy and over-treatment.  Researchers from Sunnybrook Research Institute aimed to identify non-invasive circulating miRNAs in patients that had previously undergone radical prostatectomy in order

Read More »

Webinar 2: Comprehensive Coverage of Exosome Purification and Exosomal RNA Isolation from Different Types of Liquid Biopsies

On April 17th and 18th, Norgen Biotek presented their second webinar: “Comprehensive Coverage of Exosome Purification and Exosomal RNA Isolation from Different Type of Liquid Biopsies”. Bastien Paré – a member of the R&D team, who works extensively with liquid biopsies, exosomes, RNA purifications, and small RNA NGS – facilitated the exosomal-related webinar in French and English. Topics included exosomal

Read More »
blood plasma

Researchers in Spain Identify Liver-Specific miRNAs Detected in Exosomes from HIV/HCV Patients

A group of researchers from the Institute of Health Carlos III (ISCIII) in Spain, presented a poster at the annual meeting for ISEV (International Society of Extracellular Vesicles) which analysed exosome RNA content for identification of new liver disease biomarkers. Using highthroughput NGS, the group identified multiple liver-specific miRNAs from plasma exosomes of patients who are coinfected with HIV and

Read More »

Nature Medicine: Researchers at University of California Identify Orphan Non-Coding RNA as a Promoter of Breast Cancer Metastasis

In a systematic search to identify breast-cancer-specific small non-coding RNAs, a group of researchers has discovered a novel microRNA found to be a promoter of breast cancer metastasis. They focused on this specific set of RNAs to search for a possible source of regulators capable of moderating disease pathways. They discovered 201 previously unknown small RNAs expressed solely in breast

Read More »

Molecular Med Tri-Con 2019

Norgen will be in San Francisco at the Molecular Med TRI-CON. Come by Booth #621 to visit with Norgen CEO Dr. Haj-Ahmad and Tom from Sales and Marketing. Details Conference: Molecular Med Tri-Con Date: March 10 – March 15, 2019 Booth: #621 Location: Moscone Center South, San Francisco, CA Conference Schedule < March 1March 08 – March 1415 March >

Read More »

Norgen Biotek Launches Webinar Series

On Wednesday February 20th, 2019 Norgen Biotek launched their first webinar, marking the beginning of a series of webinars scheduled for 2019. Dr. Moemen Abdalla, a senior research and development scientist with Norgen Biotek Corp., presented the first talk titled ‘Recent Advances in the Preservation and Purification of Plasma cf-DNA and cf-RNA’. In this webinar, Dr. Abdalla spoke in detail

Read More »

Norgen Biotek Issues Press Release: Norgen’s cf-DNA/cf-RNA Preservative Tubes Found Most Suitable for Liquid Biopsy Applications

Last week Norgen Biotek Corp. issued a press release highlighting a recent finding in a paper published in the International Journal of Medical Sciences by a group of researchers at the University Hospital of Heidelberg and the German Cancer Center.  The scientists conducted a comparison study testing various blood collection tubes (BCTs) from four different manufacturers. They compared Norgen’s cf-DNA/cf-RNA

Read More »
feature04

Norgen Biotek’s Plasma/Serum Cell-Free Circulating DNA Purification Kits Shown to Recover Highest Amount of Small DNA Fragments when Compared to Other Commercially Available Purification Kits

A recent study conducted by researchers at the Macquarie University in Sydney, Australia evaluated the efficiency of several commercially available kits for extracting cell-free circulating DNA from plasma samples. The study compared two spin-column based kits including the QIAmp Circulating Nucleic Acid Kit (Qiagen, Germany) and the Plasma/Serum Cell-free Circulating DNA Purification Midi Kit (Norgen Biotek, Canada) against 4 different

Read More »
Feature03

Researchers Utilize Circulating Tumor DNA to Analyze KRAS Mutations in Colorectal Cancer Patients with Liver Metastases

This past October at the European Society of Medical Oncology Congress 2018, a group of researchers from IMDL Genome Centre Bulgaria presented a poster focused on cell-free circulating tumor DNA with KRAS/EGFR mutations in metastatic colorectal cancer (mCRC) patients. The emergence of KRAS mutation during the course of anti-EGFR (epidermal growth factor receptor) therapy is responsible for acquired resistance to

Read More »
propel

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

THOROLD, ON, Nov. 20, 2018 /PRNewswire/ – Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.  Norgen’s Propel Certification covers both the NextSeq 500

Read More »

The Detection & Expression of Circulating miRNAs as Biomarkers Hold High Clinical Implications for Predicting Prostate Cancer Recurrence Post Radical Prostatectomy.

Currently, there is limited technology available for accurately predicting high-risk cancer biochemical recurrence (BCR). As such, there is a significant clinical need to discover non-invasive biomarkers in hopes to identify these high-risk patients and prevent unnecessary therapy and over-treatment.  Researchers from Sunnybrook Research Institute aimed to identify non-invasive circulating miRNAs in patients that had previously undergone radical prostatectomy in order

Read More »

Webinar 2: Comprehensive Coverage of Exosome Purification and Exosomal RNA Isolation from Different Types of Liquid Biopsies

On April 17th and 18th, Norgen Biotek presented their second webinar: “Comprehensive Coverage of Exosome Purification and Exosomal RNA Isolation from Different Type of Liquid Biopsies”. Bastien Paré – a member of the R&D team, who works extensively with liquid biopsies, exosomes, RNA purifications, and small RNA NGS – facilitated the exosomal-related webinar in French and English. Topics included exosomal

Read More »

Researchers in Spain Identify Liver-Specific miRNAs Detected in Exosomes from HIV/HCV Patients

A group of researchers from the Institute of Health Carlos III (ISCIII) in Spain, presented a poster at the annual meeting for ISEV (International Society of Extracellular Vesicles) which analysed exosome RNA content for identification of new liver disease biomarkers. Using highthroughput NGS, the group identified multiple liver-specific miRNAs from plasma exosomes of patients who are coinfected with HIV and

Read More »

Nature Medicine: Researchers at University of California Identify Orphan Non-Coding RNA as a Promoter of Breast Cancer Metastasis

In a systematic search to identify breast-cancer-specific small non-coding RNAs, a group of researchers has discovered a novel microRNA found to be a promoter of breast cancer metastasis. They focused on this specific set of RNAs to search for a possible source of regulators capable of moderating disease pathways. They discovered 201 previously unknown small RNAs expressed solely in breast

Read More »

Molecular Med Tri-Con 2019

Norgen will be in San Francisco at the Molecular Med TRI-CON. Come by Booth #621 to visit with Norgen CEO Dr. Haj-Ahmad and Tom from Sales and Marketing. Details Conference: Molecular Med Tri-Con Date: March 10 – March 15, 2019 Booth: #621 Location: Moscone Center South, San Francisco, CA Conference Schedule < March 1March 08 – March 1415 March >

Read More »

Norgen Biotek Launches Webinar Series

On Wednesday February 20th, 2019 Norgen Biotek launched their first webinar, marking the beginning of a series of webinars scheduled for 2019. Dr. Moemen Abdalla, a senior research and development scientist with Norgen Biotek Corp., presented the first talk titled ‘Recent Advances in the Preservation and Purification of Plasma cf-DNA and cf-RNA’. In this webinar, Dr. Abdalla spoke in detail

Read More »

Norgen Biotek Issues Press Release: Norgen’s cf-DNA/cf-RNA Preservative Tubes Found Most Suitable for Liquid Biopsy Applications

Last week Norgen Biotek Corp. issued a press release highlighting a recent finding in a paper published in the International Journal of Medical Sciences by a group of researchers at the University Hospital of Heidelberg and the German Cancer Center.  The scientists conducted a comparison study testing various blood collection tubes (BCTs) from four different manufacturers. They compared Norgen’s cf-DNA/cf-RNA

Read More »

Norgen Biotek’s Plasma/Serum Cell-Free Circulating DNA Purification Kits Shown to Recover Highest Amount of Small DNA Fragments when Compared to Other Commercially Available Purification Kits

A recent study conducted by researchers at the Macquarie University in Sydney, Australia evaluated the efficiency of several commercially available kits for extracting cell-free circulating DNA from plasma samples. The study compared two spin-column based kits including the QIAmp Circulating Nucleic Acid Kit (Qiagen, Germany) and the Plasma/Serum Cell-free Circulating DNA Purification Midi Kit (Norgen Biotek, Canada) against 4 different

Read More »

Researchers Utilize Circulating Tumor DNA to Analyze KRAS Mutations in Colorectal Cancer Patients with Liver Metastases

This past October at the European Society of Medical Oncology Congress 2018, a group of researchers from IMDL Genome Centre Bulgaria presented a poster focused on cell-free circulating tumor DNA with KRAS/EGFR mutations in metastatic colorectal cancer (mCRC) patients. The emergence of KRAS mutation during the course of anti-EGFR (epidermal growth factor receptor) therapy is responsible for acquired resistance to

Read More »

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

THOROLD, ON, Nov. 20, 2018 /PRNewswire/ – Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.  Norgen’s Propel Certification covers both the NextSeq 500

Read More »